All News

PARP inhibitors like rucaparib should be considered to treat all kinds of patients, including those who have deleterious mutations and HRD, according to Amit Oza, MD, MBBS, FRCPC.

Chiara Cremolini, MD, PhD, discussed results from the phase 3 TRIPLETE study of triplet chemotherapy plus panitumumab in previously untreated patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer.

The European Commission based its approval of nivolumab/relatlimab for patients with a PD-L1 expression of less than 1% on the results of the phase 2/3 RELATIVITY-047 trial.

One of the CRESTONE investigators, Tejas Patil, MD, assistant professor of medicine–medical oncology at the University of Colorado School of Medicine in Aurora, discussed seribantumab in previously treated patients with NRG1 fusion–positive tumors.

Catherine A. Shu, MD, spoke about the most important findings from the phase 1 CHRYSALIS-2 trial for patients with previously treated EGFR-mutant non–small cell lung cancer who are administered amivantamab plus lazertinib.

PARP inhibitors such as rucaparib appear to garner the most benefit in the early maintenance setting in patients with ovarian cancer who have less advanced disease and less heterogeneity, according to Amit Oza, MD, MBBS, FRCPC.

Doris K. Hansen, MD, discussed results of an efficacy analysis examining the BCMA-directed CAR T-cell therapy idecabtagene vicleucel in real-world treatment of patients with relapsed/refractory multiple myeloma.

Olaparib and bevacizumab has been approved in China as a frontline maintenance treatment for patients with advanced homologous recombination deficiency–positive ovarian cancer based on results from the phase 3 PAOLA-1 trial.

Anne Chiang, MD, PhD, discussed results from a pilot study of biomarkers in tumors treated with ipilimumab and nivolumab in extensive-stage small cell lung cancer.

Abiraterone and olaparib continued to demonstrate a positive trend in overall survival (OS) in patients with metastatic castration-resistant prostate cancer, according to Fred Saad, MD, FRCS, though he stated that longer follow-up is needed to confirm the benefit.

Findings from the phase 3 COSMIC-021 trial, comparing the effect of cabozantinib alone or in combination with atezolizumab vs docetaxel for advanced non–small cell lung cancer previously treated with immunotherapy, though promising, highlighted further need for randomized data to confirm the regimen’s benefit in the second-line setting, according to Joel W. Neal, MD, PhD.

Alison M. Schram, MD, spoke about key findings from the phase 2 eNRGy trial assessing zenocutuzumab in patients with NRG1 fusion–positive advanced solid tumors.

Patients with RET fusion–positive locally advanced/metastatic non–small cell lung cancer can now receive treatment with RET inhibitor selpercatinib, which was approved by the FDA.

Patients with RET fusion–positive locally advanced or metastatic solid tumors can now receive treatment with selpercatinib following its approval by the FDA.

In an interview, Kami J. Maddocks, MD, showed her excitement about future use of bispecific antibodies for the treatment of lymphomas.

Tanya Dorff, MD, spoke about how CAR T-cell therapy could be a potential new addition to the prostate cancer treatment paradigm based on data from ongoing studies.

Frequent targetable mutations in patients with extramedullary acute myeloid leukemia lends credence to the use of next-generation sequencing to determine the optimal targeted therapy approach.

Patients with pancreatic cancer may benefit from treatment with ATG-101, which was granted orphan drug designation by the FDA.

Charu Aggarwal, MD, MPH, discussed findings from a study of the replication-deficient adenovirus CAN-2409 in advanced non–small cell lung cancer.

Sodium thiosulfate, which appears to be effective in decreasing the risk for hearing loss related to treatment with cisplatin, received FDA approval in pediatric patients with localized, non-metastatic solid tumors.

The FDA has granted orphan drug designation to second-line GNS561 following the completion of a phase 1/2a trial evaluating the novel PPT1 inhibitor in liver cancer and cholangiocarcinoma.

Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.

Patients with previously treated, metastatic, HER2-positive colorectal cancer may benefit from treatment with tucatinib and trastuzumab, which was granted priority review by the FDA.

At ASCO 2022, Catherine A. Shu, MD, spoke about the CHRYSALIS-2 trial which investigated the use of amivantamab plus lazertinib in patients with EGFR-mutant non–small cell lung cancer following progression on a prior EGFR inhibitor.

Kami J. Maddocks, MD, reviews updates to a pivotal trial supporting the use of brentuximab vedotin in advanced-stage Hodgkin lymphoma and ongoing research into PD-1 inhibitors in this space.

Long-term follow-up from the phase 2 KEYNOTE-158 trial showed enduring anti-tumor activity when pembrolizumab was used to treat patients with microsatellite instability–high/mismatch repair deficient advanced endometrial cancer.

An ongoing phase 1 trial is assessing the potential of SY-5609 plus chemotherapy in patients with advanced solid tumors, with the FDA granting orphan drug designation to the combination for patients with relapsed metastatic pancreatic cancer.

The positive results from the phase 3 CheckMate76K trial suggest that recurrence-free survival may be improved following treatment with adjuvant nivolumab vs placebo in fully resected stage IIB/C melanoma.

Matthew Schabath, PhD, spoke about COLOR designed as competency training for oncologists treating patients from the LGBTQ+ community.

Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.